Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Meningeal Carcinomatosis × tucatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 11 Triple Negative Breast Neoplasms 3 Neoplasms 3 Neoplasm Metastasis 2 Multiple Myeloma 2 Meningeal Neoplasms 2 Lymphoma, Non-Hodgkin 2 Stomach Neoplasms 1 Rectal Neoplasms 1 Pathologic Complete Response 1 Meningeal Carcinomatosis 1 Hemangiosarcoma 1 HER2-positive Breast Cancer 1 Colorectal Neoplasms 1 Anatomic Stage II Breast Cancer AJCC v8 1 Adenocarcinoma 1

Interventions

Pemetrexed 11 Spinal Puncture 4 Specimen Handling 4 Magnetic Resonance Spectroscopy 4 Bevacizumab 4 aflutinib 3 Trastuzumab 2 Radiotherapy, Intensity-Modulated 2 Radiotherapy 2 tucatinib 1 trastuzumab deruxtecan 1 sintilimab 1 sacituzumab govitecan 1 pertuzumab 1 osimertinib 1 azeliragon 1 Temozolomide 1 Radiosurgery 1 Physical Examination 1 Immune Checkpoint Inhibitors 1 Drug Therapy 1 Deferoxamine 1 Craniospinal Irradiation 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05800275 2025-11-18

ETIC-LM

UNICANCER

Phase 2 Recruiting

Meningeal Neoplasms, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡